Sung Joon Jin1, Ji Hyun Yoon1, Bo Sook Ahn2, Ji Ah Chung2, Young Goo Song3. 1. Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. 2. Therapeutic Drug Monitoring Team, Gangnam Severance Hospital, Seoul, Korea. 3. Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. ; Therapeutic Drug Monitoring Team, Gangnam Severance Hospital, Seoul, Korea.
Abstract
BACKGROUND: The ratio of the steady-state 24-hour area under the concentration-time curve (ssAUC24) to the MIC (AUC24/MIC) for vancomycin has been recommended as the preferred pharmacodynamic index. The aim of this study was to assess whether the calculated AUC24 (cAUC24) using the creatinine clearance (CLcr) differs from the ssAUC24 based on the individual pharmacokinetic data estimated by a commercial software. MATERIALS AND METHODS: The cAUC24 was compared with the ssAUC24 with respect to age, body mass index, and trough concentration of vancomycin and the results were expressed as median and interquartile ranges. A correlation between the cAUC24 and ssAUC24 and the trough concentration of vancomycin was evaluated. The probability of reaching an AUC24/MIC of 400 or higher was compared between the cAUC24 and ssAUC24 for different MICs of vancomycin and different daily doses by simulation in a subgroup with a trough concentration of 10 mg/L and higher. RESULTS: The cAUC24 was significantly lower than the ssAUC24 (392.38 vs. 418.32 mg·hr/L, P < 0.0001) and correlated weakly with the trough concentration (r = 0.649 vs. r = 0.964). Assuming a MIC of 1.0 mg/L, the probability of reaching the value of 400 or higher was 77.5% for the cAUC24/MIC and 100% for the ssAUC24/MIC in patients with a trough concentration of 10 mg/L and higher. If the MIC increased to 2.0 mg/L, the probability was 57.7% for the cAUC24/MIC and 71.8% for the ssAUC24/MIC at a daily vancomycin dose of 4,000 mg. CONCLUSIONS: The cAUC24 using the calculated CLcr is usually underestimated compared with the ssAUC24 based on individual pharmacokinetic data. Therefore, to obtain a more accurate AUC24, therapeutic monitoring of vancomycin rather than a simple calculation based on the CLcr should be performed, and a more accurate biomarker for renal function is needed.
BACKGROUND: The ratio of the steady-state 24-hour area under the concentration-time curve (ssAUC24) to the MIC (AUC24/MIC) for vancomycin has been recommended as the preferred pharmacodynamic index. The aim of this study was to assess whether the calculated AUC24 (cAUC24) using the creatinine clearance (CLcr) differs from the ssAUC24 based on the individual pharmacokinetic data estimated by a commercial software. MATERIALS AND METHODS: The cAUC24 was compared with the ssAUC24 with respect to age, body mass index, and trough concentration of vancomycin and the results were expressed as median and interquartile ranges. A correlation between the cAUC24 and ssAUC24 and the trough concentration of vancomycin was evaluated. The probability of reaching an AUC24/MIC of 400 or higher was compared between the cAUC24 and ssAUC24 for different MICs of vancomycin and different daily doses by simulation in a subgroup with a trough concentration of 10 mg/L and higher. RESULTS: The cAUC24 was significantly lower than the ssAUC24 (392.38 vs. 418.32 mg·hr/L, P < 0.0001) and correlated weakly with the trough concentration (r = 0.649 vs. r = 0.964). Assuming a MIC of 1.0 mg/L, the probability of reaching the value of 400 or higher was 77.5% for the cAUC24/MIC and 100% for the ssAUC24/MIC in patients with a trough concentration of 10 mg/L and higher. If the MIC increased to 2.0 mg/L, the probability was 57.7% for the cAUC24/MIC and 71.8% for the ssAUC24/MIC at a daily vancomycin dose of 4,000 mg. CONCLUSIONS: The cAUC24 using the calculated CLcr is usually underestimated compared with the ssAUC24 based on individual pharmacokinetic data. Therefore, to obtain a more accurate AUC24, therapeutic monitoring of vancomycin rather than a simple calculation based on the CLcr should be performed, and a more accurate biomarker for renal function is needed.
Entities:
Keywords:
Area under curve; Drug monitoring, Therapeutic; Pharmacodynamics; Vancomycin
Authors: Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine Journal: Am J Health Syst Pharm Date: 2009-01-01 Impact factor: 2.637
Authors: Meghan N Jeffres; Warren Isakow; Joshua A Doherty; Peggy S McKinnon; David J Ritchie; Scott T Micek; Marin H Kollef Journal: Chest Date: 2006-10 Impact factor: 9.410
Authors: Nimish Patel; Manjunath P Pai; Keith A Rodvold; Ben Lomaestro; George L Drusano; Thomas P Lodise Journal: Clin Infect Dis Date: 2011-04-15 Impact factor: 9.079
Authors: Maria del Mar Fernández de Gatta; Dolores Santos Buelga; Amparo Sánchez Navarro; Alfonso Dominguez-Gil; Maria Jose García Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447
Authors: Ryan Marko; Julia Hajjar; Vanessa Nzeribe; Michelle Pittman; Vincent Deslandes; Nadia Sant; Juthaporn Cowan; Kwadwo Kyermentang; Tim Ramsay; Sheryl Zelenitsky; Salmaan Kanji Journal: Can J Hosp Pharm Date: 2021
Authors: Aseel K AbuSara; Deema H Abdelrahman; Khader I Habash; Mohammad H Al-Shaer; Jennifer Le; Lama H Nazer Journal: Pharmacol Res Perspect Date: 2022-02